L-asparaginase production review: bioprocess design and biochemical characteristics.
Daniel CastroAna Sofia C MarquesMafalda R AlmeidaGabriela B de PaivaHeitor B S BentoDanielle Biscaro PedrolliMara G FreireAna P M TavaresValéria Carvalho Santos EbinumaPublished in: Applied microbiology and biotechnology (2021)
In the past decades, the production of biopharmaceuticals has gained high interest due to its great sensitivity, specificity, and lower risk of negative effects to patients. Biopharmaceuticals are mostly therapeutic recombinant proteins produced through biotechnological processes. In this context, L-asparaginase (L-asparagine amidohydrolase, L-ASNase (E.C. 3.5.1.1)) is a therapeutic enzyme that has been abundantly studied by researchers due to its antineoplastic properties. As a biopharmaceutical, L-ASNase has been used in the treatment of acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), and other lymphoid malignancies, in combination with other drugs. Besides its application as a biopharmaceutical, this enzyme is widely used in food processing industries as an acrylamide mitigation agent and as a biosensor for the detection of L-asparagine in physiological fluids at nano-levels. The great demand for L-ASNase is supplied by recombinant enzymes from Escherichia coli and Erwinia chrysanthemi. However, production processes are associated to low yields and proteins associated to immunogenicity problems, which leads to the search for a better enzyme source. Considering the L-ASNase pharmacological and food importance, this review provides an overview of the current biotechnological developments in L-ASNase production and biochemical characterization aiming to improve the knowledge about its production. KEY POINTS: • Microbial enzyme applications as biopharmaceutical and in food industry • Biosynthesis process: from the microorganism to bioreactor technology • Enzyme activity and kinetic properties: crucial for the final application.
Keyphrases
- acute lymphoblastic leukemia
- escherichia coli
- end stage renal disease
- healthcare
- newly diagnosed
- chronic kidney disease
- climate change
- intensive care unit
- liver failure
- bone marrow
- risk assessment
- microbial community
- respiratory failure
- gold nanoparticles
- staphylococcus aureus
- drug induced
- prognostic factors
- mechanical ventilation
- combination therapy